C12-TLRa

C12-TLRa is an ionized adjuvant lipid. C12-TLRa targets TLR7/8 receptors in endosomes. C12-TLRa enhances mRNA delivery as a structural component of LNPs. C12-TLRa enhances innate immune responses. C12-TLRa can be used for the research of SARS-CoV-2 mRNA vaccine[1][2].

Product Specifications

CAS Number

[3067466-15-0]

UNSPSC

12352005

Target

Liposome; Toll-like Receptor (TLR)

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/c12-tlra.html

Purity

99.0

Solubility

DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C) |Ethanol : 50 mg/mL (ultrasonic)

Smiles

NC1=NC2=CC=CC=C2C3=C1N=C(CCCC)N3CC4=CC=C(CN(CC(O)CCCCCCCCCC)CC(O)CCCCCCCCCC)C=C4

Molecular Formula

C46H73N5O2

Molecular Weight

728.10

References & Citations

[1]Han X, et al. Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines. Nat Nanotechnol. 2023 Jun 26. |[2]Han EL, et al. Peptide-Functionalized Lipid Nanoparticles for Targeted Systemic mRNA Delivery to the Brain. Nano Lett. 2025 Jan 15;25 (2) :800-810.